VJHemOnc was pleased to be media partner for the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, which was held on October 23-26, 2022 in Rome, Italy, and virtually. This meeting brought together SOHO  & Italian experts in acute leukemias, MDS & MPNs with the aim of integrating the activities of the IRST IRCCS and MD Anderson Cancer Center and improving the treatment of patients with hematological malignancies. For more information on SOHO Italy, visit sohoitaly.com
View all videos

SOHO Italy 2022

The 4th SOHO Italy Annual Conference
23–26 October 2022 | Rome, Italy / Online

SOHO Italy 2022

The 4th SOHO Italy Annual Conference
23–26 October 2022 | Rome, Italy / Online
VJHemOnc was pleased to be media partner for the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, which was held on October 23-26, 2022 in Rome, Italy, and virtually. This meeting brought together SOHO  & Italian experts in acute leukemias, MDS & MPNs with the aim of integrating the activities of the IRST IRCCS and MD Anderson Cancer Center and improving the treatment of patients with hematological malignancies. For more information on SOHO Italy, visit sohoitaly.com
View all videos

Latest videos

View all
2:01
The role of MRD in CLL patients with high-risk cytogenetics & future perspectives
Massimo Massaia • 25 Oct 2022
1:11
The value of using personalized approaches when treating patients with MF
Elisabetta Abruzzese • 24 Oct 2022
4:42
The role of JAK inhibitors in treating MPNs and the need for disease-modifying agents
Elisabetta Abruzzese • 24 Oct 2022
2:14
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
Hans Lee • 25 Oct 2022

MRD

View all
1:39
The growing role of MRD as a clinical endpoint in CLL
Massimo Massaia • 25 Oct 2022
1:50
The possibility of using MRD status to drive treatment in AML
Alessandro Isidori • 24 Oct 2022
1:15
The potential role of MRD in treating CLL patients receiving continuous therapy
Massimo Massaia • 25 Oct 2022
1:39
The importance of achieving CR before stem cell transplantation in patients with AML and ALL
Francesco Lanza • 24 Oct 2022

Immuno-Oncology

View all
1:54
Treatment options for DLBCL patients who relapse after CAR-T cell therapy
Enrico Derenzini • 25 Oct 2022
1:20
Exciting research in the CAR-T space: the promise of allogeneic therapies
Massimiliano Mazza • 25 Oct 2022
2:10
Promising immunotherapeutic agents under investigation in AML: sabatolimab and magrolimab
Alessandro Isidori • 24 Oct 2022
2:14
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
Hans Lee • 25 Oct 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals